Vantage Investment Advisors’s Pacira BioSciences PCRX Stock Holding History

Vantage Investment Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	$12K	Hold	240	–	–	﹤0.01%	509
2018 Q2	$8K	Hold	240	–	–	﹤0.01%	580
2018 Q1	$7K	Hold	240	–	–	﹤0.01%	617
2017 Q4	$11K	Hold	240	–	–	﹤0.01%	565
2017 Q3	$9K	Hold	240	–	–	﹤0.01%	585
2017 Q2	$11K	Hold	240	–	–	﹤0.01%	532
2017 Q1	$11K	Buy	+240	New	+$10.4K	﹤0.01%	515
2016 Q3	–	Sell	-250	Closed	-$8K	–	824
2016 Q2	$8K	Hold	250	–	–	﹤0.01%	560
2016 Q1	$13K	Hold	250	–	–	0.01%	479
2015 Q4	$19K	Hold	250	–	–	0.01%	395
2015 Q3	$10K	Hold	250	–	–	0.01%	495
2015 Q2	$18K	Hold	250	–	–	0.01%	395
2015 Q1	$22K	Hold	250	–	–	0.01%	480
2014 Q4	$22K	Hold	250	–	–	0.01%	358
2014 Q3	$24K	Hold	250	–	–	0.01%	327
2014 Q2	$23K	Hold	250	–	–	0.01%	349
2014 Q1	$17K	Hold	250	–	–	0.01%	369
2013 Q4	$14K	Buy	+250	New	+$13.1K	0.01%	363

Other funds holding PCRX

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Vantage Investment Advisors's PCRX Position: Q3 2018 in Review

Vantage Investment Advisors held its Pacira BioSciences (PCRX) position steady in Q3 2018 at 240 shares worth $12K. The position accounts for ﹤0.01% of the portfolio, ranked #509.

Vantage Investment Advisors first reported a position in PCRX in Q4 2013 and has held it in 18 quarters since. The position peaked at $24K in Q3 2014. 187 funds tracked by Wall St. Rank hold PCRX as of Q3 2018.

Vantage Investment Advisors held 240 shares of Pacira BioSciences worth $12K as of Q3 2018.
Vantage Investment Advisors left its Pacira BioSciences share count unchanged in Q3 2018.
Pacira BioSciences made up ﹤0.01% of Vantage Investment Advisors's portfolio in Q3 2018, its #509 holding.
Vantage Investment Advisors first reported a position in Pacira BioSciences in Q4 2013 and has held it in 18 quarters since.
Vantage Investment Advisors's Pacira BioSciences position peaked at $24K in Q3 2014.
187 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2018.

Based on Vantage Investment Advisors's 13F filing for Q3 2018, filed 9 Nov 2018.